

Grifols makes public its succession plan: the envisaged generational handover reiterates the commitment of the founding family to the company

- ***From 1 January 2017 Victor Grifols Roura will be succeeded by his brother, Raimon Grifols, and his son, Víctor Grifols Deu, who will become joint and several chief executive officers of the company. Víctor Grifols will continue holding his position as non-executive chairman of the board of directors.***
- ***The succession plan proposed by the incumbent chief executive officer of Grifols has been unanimously approved by the board of directors.***
- ***The succession plan establishes 2016 as a transition year in order that the handover is carried out in a smooth and orderly manner.***

Barcelona, 14 December 2015.- The Board of Directors of Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS) has unanimously approved the "succession plan" proposed by Víctor Grifols Roura, the incumbent Chairman and Chief Executive Office of the company. He proposes to hand over his executive responsibilities to his brother, Raimon Grifols Roura, and his son, Víctor Grifols Deu, who will become joint and several chief executive officers of the company from 1 January 2017. Víctor Grifols will continue holding his position as non-executive chairman of the board of directors. The plan has been previously evaluated by the Remunerations and Appointment Committee of Grifols.

The plan also establishes 2016 as a transition year in order that the handover is carried out in a smooth and orderly manner.

The incumbent chairman and chief executive officer of Grifols feels that *"it is now time to hand over the executive responsibility of Grifols to a new generation that is well prepared and ready to reach the same level of success we have achieved since 1987. I am not worried because I have placed my confidence in the best candidates. Both are equally if not even better acquainted with the company than me and their youth and skills will bring added value to face the company's future challenges. But I am not retiring from the company entirely; you can count on my support, experience and expertise, which I shall continue providing from my position as the non-executive chairman of the board of directors"*.

Raimon Grifols Roura and Víctor Grifols Deu have complementary profiles. Both of them hold the company in high regard and are fully committed and dedicated to it. This generational handover therefore reiterates the commitment of the founding family to the company and reinforces its determination to ensure the continuity of the spirit and values that have enabled Grifols to become a leading company in the development of life-saving plasma medicines throughout its 75 years of history.

Víctor Grifols Roura, who will be 67 years old in 2017, intends to be succeeded as chief executive officer at the same age as his father, Víctor Grifols Lucas, was succeeded by him. Víctor Grifols Roura joined Grifols in 1973, assumed the commercial management of the company in 1979 and became the chief executive of the company in 1987. His entrepreneurial vision has been the perfect complement to the high scientific and innovative standards that have characterized the company since his grandfather, José Antonio Grifols Roig, and his father and his uncle, Víctor and José Antonio Grifols Lucas, founded Laboratorios Grifols in 1940.

The succession plan's details:

- Víctor Grifols Roura will remain in office as chairman and chief executive officer until 31 December 2016.
- Víctor Grifols Deu will be appointed as executive director in the next Ordinary Shareholders' Meeting to be held in 2016.
- Raimon Grifols Roura and Víctor Grifols Deu will be appointed as joint and several chief executive officers on 1 January 2017.
- Víctor Grifols Roura will continue holding his position as the non-executive chairman of the board of directors from 1 January 2017.
- Thomas Glanzmann will be appointed as non-executive vice-secretary to the board of directors on 1 January 2017.

About Grifols: 75 Anniversary of improving people's health

Grifols is a global healthcare company founded in 1940. In 2015 Grifols celebrated its 75th Anniversary of improving people's health and well being through the development of life-saving plasma medicines, diagnostics systems, and hospital pharmacy products.

The company is present in more than 100 countries worldwide and is headquartered in Barcelona, Spain. Grifols is a leader in plasma collection with a network of 150 plasma donor centers in the U.S., and a leading producer of plasma-derived biological medicines. The company also provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood tanks and transfusion centers, and is a recognized leader in transfusion medicine.

In 2014, income exceeded 3,350 million euros with a headcount close to 14,000 employees. Grifols demonstrates its commitment to advancing healthcare by allocating a significant portion of its annual income to R&D.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Its non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ via ADRs (NASDAQ:GRFS). For more information visit www.grifols.com.
